Based in Venlo, the Netherlands, QIAGEN N.V. is one of the world’s leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its oncology diagnostics portfolio with two strategic partnerships to advance the use of minimal residual ...

Under the terms of the agreement, ID Solutions will produce and supply dPCR assays specifically for non-clinical research use on Qiagen’s QIAcuity platforms. These assays are designed to ...

On Friday, Qiagen (NYSE:QGEN) announced a new commercial collaboration and joint marketing agreement with French company ID Solutions to expand the availability of digital polymerase chain ...

The collaboration supports Qiagen’s focus on expediting the QIAcuity dPCR platform adoption in oncology research. Credit: T Schneider / Shutterstock. Qiagen has entered a commercial collaboration and ...

VENLO, Netherlands, May 22, 2025--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing agreement with ID Solutions ...

‡ Otology - Cochlear Implant Unit, Department of Neuroscience, University of Pisa, Via Paradisa 2 Pisa, 56124, Italy § Department of Human Morphology & Applied Biology, University of Pisa, Via Roma 55 ...